CANNX brings to light exciting developments in the medical cannabis market

In Israel, cannabis is a highly regarded plant. The country is considered to be one of the major players of cannabis research and production, so it is no surprise that it also hosts one of the largest cannabis-related events that aim to provide knowledge on how it can be effectively used for medicinal treatment. THC and CBD stimulate the body’s endocannabinoid system to promote overall health.

Cannabis, once a highly addictive substance and regarded as illegal, has rapidly transformed into a useful medical substance. Israel regards cannabis very highly.

The country considers itself to be one of the major players of cannabis research and production. It is no surprise that it also hosts one of the largest cannabis-related events. They aim to provide knowledge and insights on how it can be effectively used for medicinal treatment.

Cannabis in Israel

The Conference Chair and a Keynote Speaker, Dr. Ralph Mechoulam is widely regarded as the father of modern medical cannabis due to his discoveries. His research promotes a more widespread understanding of how cannabis affects the body. His findings include the endocannabinoid system as well as the two main cannabinoids THC and CBD.

Through his lifelong efforts, we now understand how THC and CBD stimulate the body’s endocannabinoid system. It promotes overall health and increase its capabilities of fighting off diseases and other external threats.

Startup support

The concluded cannabis event will also provide educational workshops, investment insights into various cannabis brands. Even startup accelerator services for entrepreneurs looking to further develop their cannabis enterprise visions. Cannabis startups have been a subject of interest for entrepreneurship. This aligns with the younger generation exhibiting a strong pro-cannabis mentality.

Cann 10 is on hand at the event to promote various startups in the medical cannabis field. Furthermore, the event hosts the Innovation Award for pre-seed and seed-stage cannabis technology startups demonstrating innovative new approaches to incorporating cannabis into various business ventures.

Sound partnership

FSD Pharma’s R&D partner SciCann Therapeutics is an Israel-based pharmaceutical company that focuses on the innovative and effective implementation of cannabis as a source of medicinal treatment for pain, inflammatory disorders, oncology, and others.

Another goal behind the program was to fuel research efforts to incorporate cannabis as a treatment method for atherosclerosis. This highlights the added interest and belief that cannabis pharmaceuticals will eventually replace current treatments. Treatments such as prescription drugs and opiates which can be dangerous and cause addictions. SciCann Therapeutics strives to promote cannabis as a safe alternative with proven medicinal capabilities corroborated by clinical trial discoveries.

The conference has become a well-known event that brings together some of the various presences in the cannabis sector. This includes corporate brands and ancillary businesses. They look to establish strong business relationships and partnerships to further improve the cannabis industry. 

—

(Featured Image by Gage Skidmore via Flickr. CC BY-SA 2.0.)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof.